Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 15, Pages -Publisher
MDPI
DOI: 10.3390/jcm11154453
Keywords
monoclonal antibodies; biologics; chronic spontaneous urticaria; treatment; children; adults
Categories
Ask authors/readers for more resources
Omalizumab remains the best choice for treating refractory CSU, but some patients remain unresponsive. Other mAbs targeting different pathways have shown promising results, but further RCTs are needed to confirm their effectiveness and safety.
Background: H1-antihistamines (H1AH) represent the current mainstay of treatment for chronic spontaneous urticaria (CSU). However, the response to H1AH is often unsatisfactory, even with increased doses. Therefore, guidelines recommend the use of omalizumab as an add-on treatment in refractory CSU. This paved the way for the investigation of targeted therapies, such as monoclonal antibodies (mAbs), in CSU. Methods: A literature review was conducted including papers published between 2009 and 2022 and ongoing trials about the efficacy and safety of mAbs as treatment for CSU. Results: Twenty-nine articles, a trial with preliminary results, and seventeen ongoing or completed clinical trials on the use of mAbs in CSU were included. Randomized controlled trials (RCTs), meta-analysis, and real-life studies have proven the effectiveness and safety of omalizumab as a third-line treatment in refractory CSU. However, a percentage of patients remain unresponsive to omalizumab. Therefore, other mAbs, targeting different pathways, have been used off-label in case series and others are under investigation in RCTs. Most of them have showed promising results. Conclusions: Omalizumab remains the best choice to treat refractory CSU. Although results from other mAbs seem to be encouraging to achieve symptom control in refractory CSU, thus improving patients' QoL, RCTs are needed to confirm their effectiveness and safety.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available